Erratum for Maki KC, et al. "Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women with Mixed Dyslipidemia" Am J Cardiol 2008;102:429-433 (DOI:10.1016/j.amjcard.2008.03.078);Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia

American Journal of Cardiology

Volumn 102, Issue 4, 2008, Pages 429-433

  Maki, Kevin C ^a   McKenney, James M ^b   Reeves, Matthew S ^a   Lubin, Barry C ^c   Dicklin, Mary R ^a  

^a Provident Clinical Research   (United States)

^b National Clinical Research Inc   (United States)

^c Hampton Roads Center for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ESTER DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; OMEGA 3 FATTY ACID; PLACEBO; PRESCRIPTION OMEGA 3 ACID ETHYL ESTER; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET; DYSLIPIDEMIA; DYSPEPSIA; EDUCATION PROGRAM; FEMALE; GENERALIZED EDEMA; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MYALGIA; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SIDE EFFECT; SINUSITIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

EID: 50949102978     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.077     Document Type: Erratum

References (26)

1. Davidson M.H., Stein E.A., Bays H.E., Maki K.C., Doyle R.T., Shalwitz R.A., Ballantyne C.M., Ginsberg H.N., and COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemia patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29 (2007) 1354-1367
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
3. Myers G.L., Kimberly M.M., Waymack P.P., Smith S.J., Cooper G.R., and Sampson E.J. A reference method laboratory network for cholesterol: a model for standardization and improvement of clinical laboratory measurements. Clin Chem 46 (2006) 1762-1772
4. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
5. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., Bloomfield H.E., and Robins S.J. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorable changes by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
6. Block R.C., Harris W.S., Reid K.J., Sands S.A., and Spertus J.A. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 197 (2008) 821-828
7. Nordøy A., Bonaa K.H., Nilsen H., Berge R.K., Hansen J.B., and Ingebretsen O.C. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 243 (1998) 163-170
8. Durrington P., Bhatnagar D., Mackness M., Morgan J., Julier K., Khan M.A., and France M. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin-treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart 85 (2001) 544-548
9. Sullivan D.R., Sanders T.A.B., Trayner I.M., and Thompson G.R. Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridemic patients and normal subjects ingesting fish oil. Atherosclerosis 61 (1986) 129-134
10. Harris W.S. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65 suppl (1997) 1645S-1654S
11. Huff M.W., and Telford D.E. Dietary fish oil increases conversion of very low density lipoprotein apo B to low density lipoprotein. Arteriosclerosis 9 (1989) 58-66
12. Calabresi L., Donati D., Pazzucconi F., Sirtori C., and Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low-density lipoprotein subclasses. Atherosclerosis 148 (2000) 387-396
13. Chan D.C., Watts G.F., Barrett P.H.R., Beilin L.J., Redgrave T.G., and Mori T.A. Regulatory effects of HMG CoA reductase inhibitors and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 51 (2002) 2377-2386
14. Chan D.C., Watts G.F., Mori T.A., Barrett H.R., Redgrave T.G., and Beilin L.J. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 77 (2003) 300-307
15. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 (2004) 381-387
16. Harris W.S., Ginsberg H., Arunakul N., Shachter N.S., Windsor S.L., Adams M., Berglund L., and Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 4 (1997) 385-391
17. Pownall H., Brauchi D., Kilinc C., Osmundsen K., Pao Q., Payton-Ross C., Gotto Jr. A.M., and Ballantyne C.M. Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid composition of high-density and low-density lipoproteins. Atherosclerosis 143 (1999) 285-297
18. McKenney J.M., and Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27 (2007) 715-728
19. Roche H.M., and Gibney M.J. Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Lipids 34 suppl (1999) S259-S265
20. Bucher H., Hengstler P., Schindler C., and Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112 (2002) 298-304
21. Dagnelie P.C., Rietveld T., Swart G.R., Stijinen T., and van den Berg J.W. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies, and triacylglycerol in humans. Lipids 29 (1994) 41-45
22. Harris W.S., Lu G., Rambjør G.S., Wålen A.I., Ontko J.A., Cheng Q., and Windsor S.L. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr 66 (1997) 254-260
23. Appel L.J., Miller III E.R., Seidler A.J., and Whelton P.K. Does supplementation of diet with "fish oil" reduce blood pressure?. A meta-analysis of controlled clinical trials. Arch Intern Med 153 (1993) 1429-1438
24. Morris M.C., Sacks F., and Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88 (1993) 523-533
25. Geleijnse J.M., Giltay E.J., Grobbee D.E., Donders A.R., and Kok F.J. Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. J Hypertens 20 (2002) 1493-1499
26. Hartweg J., Farmer A.J., Holman R.R., and Neil H.A. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 50 (2007) 250-258